StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Laxmikant Shukla, YES Securities

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byLaxmikant Shukla, YES SecuritiesHorizon: NA (inferred Swing (≤2wk))20 May 2026via ET Now

Entry₹2,370Stated
Target₹2,580
Total upside +8.86% (call closed)
Stop loss₹2,290-3.38% risk
Exit₹2,29022 May 2026, 12:00 pm
Stop-loss hit-3.38%
Follow Laxmikant Shukla for new calls(29% target hit, 111 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 134 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 1:54 pm IST
3 supporting0 opposing
Supports the BUY call (3)

Glenmark Pharmaceuticals' subsidiary, Ichnos Glenmark Innovation (IGI), has announced a new development candidate, ISB 2301. This is a first-in-class multispecific immune cells activator designed to t

NSE · Press Release·20 May · yesterday

(opens in new tab)

Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP in 500mg/vial and 1 g/vial strengths.

NSE · Press Release·18 May · 4d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·18 May · 4d ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Laxmikant Shukla, YES Securities

Every call and its outcome